 Nes-Ziona, March 09, 2020 GLOBE NEWSWIRE -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent 239236 covering ALLOCETRATM, the companys immunotherapy candidate. This new patent adds intellectual property protection, including methods, uses and pharmaceutical compositions in Israel. Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. 